London-based Zenithon says, via investor Seraphim, that it has raised a 10 million dollar initial round led by Backed VC to build AI world models that speed up simulation of extreme physics for engineering teams.
Isomorphic Labs raises $5 billion Series C to scale its AI drug design engine
EditorialBy TrustList Editorial
Greenoaks and Sequoia Capital co-led the round with Alphabet investing again; two days later the AI drug discovery company announced a research collaboration with MSD.
About Isomorphic Labs raises $5 billion Series C to scale its AI drug design engine
Isomorphic Labs raises $5 billion Series C to scale its AI drug design engine
17 November 2026: Isomorphic Labs, the Alphabet-backed company that designs medicines with AI, says it has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. Alphabet made what the company calls a continued significant investment, and the money goes into its drug design engine, IsoDDE, and the pipeline of drug candidates built with it.
Not yet independently verified. The round rests on Isomorphic Labs' own announcement of 17 November 2026, read on 20 November; its full news release is a PDF we have not read. The company states no valuation, and the quotes and earlier round sizes reported in the press are left out here. We will update this when it can be confirmed, and remove this note.
Who is in the round
Andreessen Horowitz (a16z) joins as a new investor alongside several others the announcement does not name. Every existing investor took part again:
- Thrive Capital
- MGX
- GV and CapitalG, Alphabet's two investment arms
- Temasek
- the UK Sovereign AI Fund
The presence of the UK Sovereign AI Fund is the detail a British reader will notice. It puts British public money next to some of the largest private technology investors in a single company.
What the money is for
Isomorphic says the funding will speed up its scientific work and its own AI development. Two things are named. The first is IsoDDE, which the company describes as a modality-agnostic drug design engine made of foundational AI models, meaning it is meant to work across different kinds of drug rather than one chemical class. The second is the pipeline of therapeutic candidates designed with it.
The company gives no valuation, no revenue figure and no timetable for its first trials in the announcement.
A pharmaceutical partner two days later
On 19 November Isomorphic announced a strategic research collaboration with MSD, the name Merck & Co. uses outside the US and Canada. The deal combines Isomorphic's AI approach with what it calls MSD's rich proprietary data resources and deep discovery experience. No financial terms, target diseases or milestones are stated.
The pattern is familiar in AI drug discovery: the model builder brings the computation, the drug maker brings years of experimental data that no public set contains. For Isomorphic the value lies as much in the data as in any payment.
Where it sits in our catalogue
Isomorphic Labs does not yet have a listing with us. Our artificial intelligence company category lists 1,121 businesses, most of them selling software to other companies rather than developing medicines. For procurement teams the round matters mainly as a signal of how much capital is now going into AI built for one scientific field rather than general-purpose models.
Company profile on TrustList: Isomorphic Labs
Sources
Categories & features
TrustList Weekly
The week in software and IT, in one email
The news that matters to buyers, new rankings and our own research. Every Thursday, free, and easy to leave.
You may be interested in
Playground Global leads the London company's round, Eka Ventures joins, and former Medtronic chief executive Omar Ishrak becomes chair; its software has been used in more than 100 operations.
Each competition opens on 21 October and closes at 11:00 UK time on 8 December; the lead must be a UK AI SME with a product at technology readiness level 5 to 6.
Frontier AI: SME Champions Phase 1 opens 1 October and closes 11 November (projects £150,000-£250,000). Efficient, Structured and Controllable AI Systems opens 12 October and closes 18 November (£50,000-£150,000).
The start-up lists Stanford professor Yejin Choi and co-chief executive Prithviraj Ammanabrolu on its team; it has not published the investors or the stage itself.
CapitalG led the Series C, with GIC and DFJ Growth joining, and LangChain says more than 7,000 organisations already run, test or govern agents on LangSmith.
Kleiner Perkins and Clearlake Capital lead the round, with Google and Battery Ventures joining, three weeks after Mirendil said one researcher with agents pretrained a coding model for under $10 million in compute.
Inovia Capital led the seed round for the synthetic data company, which launched publicly at NVIDIA GTC in March. Its first app, Studio, is free during a beta open to research teams in waves.
More on TrustList
Everything here links back to the same verified catalogue. Pick your next stop.
- More United KingdomThe ranking for this subject
- CompaniesAgencies, consultancies and IT service providers, ranked by verified reviews.
- ProductsSoftware and SaaS with pricing, features, integrations and alternatives.
- AwardsAnnual recognition decided by verified reviews and an independent jury.
- LaunchesNew products and releases, voted up by the community every day.
- AI ModelsBenchmark scores and community ratings for every major model.
- RequestsBuyers describe what they need; vendors respond directly.
- PeopleReviewers, authors and makers with public profiles.
- ComparePut up to four listings side by side before you shortlist.